Phase Ib/IIa Study of Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Carfilzomib (Primary) ; Lenalidomide (Primary) ; Romidepsin (Primary)
- Indications B cell lymphoma; T cell lymphoma
- Focus Adverse reactions
- 08 Feb 2017 Planned number of patients changed from 30 to 31.
- 08 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
- 08 Feb 2017 Status changed from recruiting to active, no longer recruiting.